Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Guizhounli Pharmaceutical Co Days Payable?
Guizhounli Pharmaceutical CoSHSE:603439 -4.86%90 Days Payable is 94.80 as of Mar. 2026, which is 24% above its 10-year median of 76.58. GuruFocus rates SHSE:603439 with a GF Score™ of 90/100 and a GF Value™ of ¥14.83 (Significantly Undervalued). The stock has 10 warning signs investors should review. Among 925 Drug Manufacturers companies, Guizhounli Pharmaceutical Co ranks better than 71.46% on this metric.
The historical rank and industry rank for Guizhounli Pharmaceutical Co's Days Payable or its related term are showing as below:
SHSE:603439'
s Days Payable Range Over the Past 10 Years
Min: 33.75 Med: 76.58 Max: 197.87
Current: 138.64
During the past 13 years, Guizhounli Pharmaceutical Co's highest Days Payable was 197.87. The lowest was 33.75. And the median was 76.58.
SHSE:603439's Days Payable is ranked better than 71.46% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SHSE:603439: 138.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's Days Payable falls into.
Guizhounli Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co (SHSE:603439) has a Days Payable of 94.80 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guizhounli Pharmaceutical Co and its competitors. This is 24% above median its historical median of 76.58. Over the past decade, Guizhounli Pharmaceutical Co's Days Payable has ranged from 33.75 to 197.87. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #264 out of 925 companies in the Drug Manufacturers industry, placing it in the top 28.5%.
Is Guizhounli Pharmaceutical Co's Days Payable too high?
Guizhounli Pharmaceutical Co's current Days Payable of 94.80 is 24% above median its 10-year median of 76.58. Over the past 10 years, this metric has ranged from a low of 33.75 to a high of 197.87. The Drug Manufacturers industry median Days Payable is 90.38. Guizhounli Pharmaceutical Co's value of 94.80 is 4.9% above this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #264 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #264 out of 925 companies for Days Payable. This puts Guizhounli Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 90.38. Guizhounli Pharmaceutical Co's value of 94.80 is 4.9% above this benchmark. Historically, Guizhounli Pharmaceutical Co's own Days Payable has ranged from 33.75 to 197.87 over the past decade. While the company's 10-year median is 76.58 vs. the industry median of 90.38, Guizhounli Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current Days Payable of 94.80 is 4.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current Days Payable is 94.80, which is 24% above median its own 10-year median of 76.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.83, compared to a current price of ¥9.99 — trading 32.6% below its estimated fair value. The current Days Payable is 94.80, which is 24% above median its 10-year median of 76.58 and 4.9% above the Drug Manufacturers industry median of 90.38. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Days Payable is 94.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥9.99 is trading 32.6% below its estimated GF Value™ of ¥14.83.
GuruFocus considers Guizhounli Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603439:
Days Payable: 94.80 (24% above median its 10-year median of 76.58)
GF Value™: ¥14.83 vs. price of ¥9.99 (32.6% below fair value)
Industry Position: 4.9% above the Drug Manufacturers median (#264 of 925)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
